Indicated in combination by having an aromatase inhibitor as Original endocrine-centered therapy for HR-favourable, HER2-negative Superior or metastatic breast cancer Metabolism Datopotamab deruxtecan-dlnk undergoes intracellular cleavage by lysosomal enzymes to launch DXd. The humanized Trop-two